← Back to Search

Other

Intervention for COVID-19

Phase 1 & 2
Waitlist Available
Led By Craig Selzman, MD
Research Sponsored by University of Utah
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months post-discharge
Awards & highlights

Study Summary

This study is evaluating whether a specific type of fluid may help treat a rare disease.

Eligible Conditions
  • COVID-19

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months post-discharge
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months post-discharge for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
C-reactive Protein
Other outcome measures
Any ICU Admission
Biomarker Levels (D-dimer)
Biomarker Levels (Interleukin-6)
+10 more

Side effects data

From 2023 Phase 1 & 2 trial • 47 Patients • NCT04497389
17%
Hypotension
17%
Bradycardia
13%
Tachycardia
13%
Abnormal CBC
8%
Abnormal Metabolic Panel
8%
Abnormal Hepatic Panel
4%
Abnormal Blood Gas
4%
Pneumothorax
4%
ED visits
4%
Abdominal pain
4%
Intubation
4%
Readmission for COVID-19 pneumonia
4%
Readmission for COVID-19 symptoms
100%
80%
60%
40%
20%
0%
Study treatment Arm
Standard of Care
Intervention

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: InterventionExperimental Treatment1 Intervention
10ml intravenous hAF QD (once daily) for 5 consecutive days
Group II: Standard of CareActive Control1 Intervention
10 mL normal saline QD (once daily) for 5 days
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Human Amniotic Fluid
Not yet FDA approved

Find a Location

Who is running the clinical trial?

University of UtahLead Sponsor
1,099 Previous Clinical Trials
1,778,642 Total Patients Enrolled
14 Trials studying COVID-19
480,599 Patients Enrolled for COVID-19
Craig Selzman, MDPrincipal Investigator - University of Utah
University of Utah Hospital
Baylor College Of Medicine (Medical School)
University Co Hlth Sci Center (Residency)
1 Previous Clinical Trials
10 Total Patients Enrolled
1 Trials studying COVID-19
10 Patients Enrolled for COVID-19

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Safety and Feasibility of Amniotic Fluid as a Treatment for COVID-19 Patients
Craig Selzman 2020. "Safety and Feasibility of Amniotic Fluid as a Treatment for COVID-19 Patients". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04497389.
~11 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top